Company intelligence / Profile preview

Curesponse

Israel

Ownership: Private
Development stage: Other

Overview

cResponse™ is a CE-marked, AI-driven genomic-functional platform for drug response prediction in living tumor tissue across chemotherapy, targeted biologics, and immunotherapies, assisting oncologists in personalized treatment selection.

Therapeutic areas: Oncology
Industry: Molecular Diagnostics

Partnerships

Imperial College LondonTel Aviv Sourasky Medical Center (Ichilov Hospital)Sheba Medical CenterRambam HospitalMigdal insurance companyLeading pharma companies

Beyond the preview

Go deeper on Curesponse.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curesponse.

Explore the full profile